Announcement PDF Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 1 / 6 Announcement Summary Entity name PERCHERON THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Wednesday October 14, 2026 The +securities to be quoted are: Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue. 138,000,000 fully paid ordinary shares at an issue price of $0.005 per share are being issued in accordance with the Appendix 3B lodged on 1 September 2026. The previously lodged Appendix 3B will not link to this Appendix 2A. Total number of +securities to be quoted ASX +security code Security description Number of +securities to be quoted Issue date PER ORDINARY FULLY PAID 138,000,000 15/10/2026 Refer to next page for full details of the announcement Other Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 2 / 6 Part 1 - Entity and announcement details 1.1 Name of entity PERCHERON THERAPEUTICS LIMITED We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules. 1.2 Registered number type ABN Registration number 41095060745 1.3 ASX issuer code PER 1.4 The announcement is 1.5 Date of this announcement 14/10/2026 New announcement Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 3 / 6 Part 2 - Type of Issue 2.1 The +securities to be quoted are: Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue. 2.2 The +class of +securities to be quoted is: 2.3c Have these +securities been offered under a +disclosure document or +PDS? 2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B 138,000,000 fully paid ordinary shares at an issue price of $0.005 per share are being issued in accordance with the Appendix 3B lodged on 1 September 2026. The previously lodged Appendix 3B will not link to this Appendix 2A. 2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of: The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f) No Additional +securities in a class that is already quoted on ASX ("existing class") Other Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 4 / 6 Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B Additional +securities to be quoted in an existing class ASX +security code and description PER : ORDINARY FULLY PAID Issue date 15/10/2026 Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class? Issue details Number of +securities to be quoted 138,000,000 Are the +securities being issued for a cash consideration? In what currency is the cash consideration being paid? AUD - Australian Dollar What is the issue price per +security? AUD 0.00500000 Any other information the entity wishes to provide about the +securities to be quoted The purpose(s) for which the entity is issuing the securities Other Please provide additional details The proceeds from the placement will be applied towards funding the recently announced investigator sponsored study in AML to be conducted by Vanderbilt Health. Yes Yes Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 5 / 6 Part 4 - Issued capital following quotation Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise: The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing. 4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application) ASX +security code and description Total number of +securities on issue PER : ORDINARY FULLY PAID 1,960,415,536 4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX) ASX +security code and description Total number of +securities on issue PERAO : OPTION EXPIRING 20-MAY-2028 EX $0.035 107,053,966 PERAR : PERFORMANCE RESTRICTED STOCK UNITS 75,000,000 PERAI : OPTION EXPIRING 07-AUG-2028 EX $0.07 5,017,500 PERAQ : OPTION EXPIRING 15-APR-2028 EX $0.01 294,987,505 PERAJ : OPTION EXPIRING 30-JUN-2028 EX $0.061 3,000,000 PERAL : OPTION EXPIRING 29-NOV-2029 EX $0.26 4,036,487 PERAN : OPTION EXPIRING 29-NOV-2029 EX $0.52 4,036,486 PERAM : OPTION EXPIRING 29-NOV-2029 EX $0.39 4,036,487 PERAB : OPTION EXPIRING 03-JUL-2031 EX $0.004 8,100,000 PERAK : OPTION EXPIRING 04-JUL-2029 EX $0.083 9,000,000 Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 6 / 6 Part 5 - Other Listing Rule requirements 5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1? 5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1? 5.2a Date of meeting or proposed meeting to approve the issue under listing rule 7.1 8/10/2026 Yes No